GRAIL, a commercial-stage healthcare company specializing in early cancer detection, reported Q1 2024 revenue of $26.7M with cash and equivalents of $199.7M. The company maintains $193.2M in money market funds and $15.0M in net accounts receivable, operating under a mandate to separate from Illumina.The European Commission approved GRAIL's divestment plan on April 12, 2024, with Illumina required to provide funding through the divestiture period, including 2.5 years of funding post-capital markets transaction. The company's employee compensation includes a Cash-Based Equity Award program with $278.6M outstanding and performance-based awards up to $78.0M.GRAIL continues to operate as a going concern with sufficient working capital for the next 12 months, despite ongoing regulatory proceedings. The company maintains strategic relationships with Illumina for reagents and equipment supply, while working toward finalizing spin-off terms by Q2 2024.

GRAIL, a commercial-stage healthcare company specializing in early cancer detection, reported Q1 2024 revenue of $26.7M with cash and equivalents of $199.7M. The company maintains $193.2M in money market funds and $15.0M in net accounts receivable, operating under a mandate to separate from Illumina.The European Commission approved GRAIL's divestment plan on April 12, 2024, with Illumina required to provide funding through the divestiture period, including 2.5 years of funding post-capital markets transaction. The company's employee compensation includes a Cash-Based Equity Award program with $278.6M outstanding and performance-based awards up to $78.0M.GRAIL continues to operate as a going concern with sufficient working capital for the next 12 months, despite ongoing regulatory proceedings. The company maintains strategic relationships with Illumina for reagents and equipment supply, while working toward finalizing spin-off terms by Q2 2024.